Sahajanand Medical Technologies Limited (NSE:SMT)
495.70
+2.80 (0.57%)
Nov 11, 2026, 1:14 PM IST
NSE:SMT Revenue
Sahajanand Medical Technologies had revenue of 3.76B INR in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to 13.55B. In the fiscal year ending March 31, 2026, Sahajanand Medical Technologies had annual revenue of 12.11B with 18.11% growth. That makes Sahajanand Medical Technologies the 19,922nd largest company in the world by revenue and 1,127th in India.
Revenue (ttm)
13.55B
Revenue Growth
+18.11%
P/S Ratio
3.61
Revenue / Employee
8.93M
Employees
1,605
Market Cap
48.76B
Revenue by Geography
- Europe 4.68B 38.7%
- Rest of World 4.26B 35.2%
- India 3.16B 26.1%
Fiscal year ended Mar 31, 2026 See the full NSE:SMT breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 12.11B | 1.86B | 18.11% |
| Mar 31, 2025 | 10.25B | 1.23B | 13.67% |
| Mar 31, 2024 | 9.02B | 1.06B | 13.33% |
| Mar 31, 2023 | 7.96B | 1.06B | 15.37% |
| Mar 31, 2022 | 6.90B | 993.37M | 16.83% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 616.31B |
| Divi's Laboratories | 121.91B |
| Lenskart Solutions | 103.83B |
| Laurus Labs | 78.23B |
| Artemis Medicare Services | 11.50B |
| SMS Pharmaceuticals | 9.74B |
| Supriya Lifescience | 8.79B |
| Orchid Pharma | 8.52B |
Sahajanand Medical Technologies News
- 5 days ago - Sahajanand Medical Technologies Transcript: Q2 26/27 - Transcripts
- 5 days ago - Sahajanand Medical Technologies Quarterly report: Q2 2027 - Filings
- 5 days ago - Sahajanand Medical Technologies Slides: Q2 2027 - Filings